Published:  10 December 2015

Mycophenolate Mofetil: Contraindicated in Pregnancy

Prescriber Update 36(4): 49
December 2015

The data sheets for mycophenolate mofetil products (CellCept) are being updated to include new contraindications. Mycophenolate will be contraindicated in:

Mycophenolate mofetil is currently categorised as a Category D medicine. This is a medicine that is suspected to have caused, or may be expected to cause, an increased incidence of human foetal malformations or irreversible damage. Based on new information the company are updating this warning to a contraindication. Healthcare professionals should inform and counsel patients of reproductive potential about the pregnancy associated risks of mycophenolate mofetil and the need to use effective contraception for both female and male patients.

Updated data sheets will be published on the Medsafe website (